Table 1.
Demographics and baseline disease characteristics
| Galcanezumab 120 mg (N = 261) | Placebo (N = 259) | |
|---|---|---|
| Age, years | 37.2 (9.3) | 36.8 (9.8) |
| Females, n (%) | 188 (72.0) | 196 (75.7) |
| Race, n (%) | ||
| Asian | 239 (91.6) | 239 (92.3) |
| White | 22 (8.4) | 20 (7.7) |
| Body mass index, kg/m2 | 23.4 (3.8) | 22.5 (3.2) |
| Region, n (%) | ||
| China | 198 (75.9) | 198 (76.4) |
| India | 41 (15.7) | 41 (15.8) |
| Russia | 22 (8.4) | 20 (7.7) |
| MHDs per month, n (%) | 8.2 (2.8) | 8.3 (2.7) |
| MHDs with acute medication use per month | 5.4 (4.9) | 4.9 (4.5) |
| Migraine frequency, n (%) | ||
| < 8 | 119 (45.6) | 113 (43.6) |
| ≥ 8 | 142 (54.4) | 146 (56.4) |
| Duration of migraine illness, years | 12.8 (9.2) | 12.4 (8.2) |
| ICHD MHDs per month, n (%) | 6.3 (3.3) | 6.3 (3.2) |
| Headache days per month, n (%) | 9.1 (3.3) | 9.1 (2.9) |
| Migraine attacks per month, n (%) | 5.5 (1.9) | 5.6 (1.7) |
| MSQ score | ||
| Total | 61.7 (15.8) | 62.1 (15.7) |
| Role Function-Restrictive | 56.0 (15.2) | 57.2 (15.2) |
| Role Function-Preventive | 66.2 (18.5) | 65.9 (17.8) |
| Emotional Function | 69.0 (22.2) | 68.5 (21.9) |
| PGI-S | 4.4 (1.3) | 4.3 (1.3) |
| MIDAS total score | 47.7 (37.2) | 45.6 (38.6) |
| ≥ 1 prior migraine medication, n (%) | 112 (42.9) | 120 (46.3) |
Data are presented as mean (standard deviation) unless otherwise specified
ICHD International Classification of Headache Disorders, MHD Migraine headache day, MIDAS Migraine Disability Assessment, MSQ Migraine Specific Quality of Life Questionnaire, N Number of patients in the analysis population, n number of patients within each specific category, PGI-S Patient Global Impression of Severity